Micronization Agents Lonza Acquires Micronization Specialist Micro-Macinazione
Lonza has acquired Micro-Macinazione, a contract manufacturer providing micronization of active ingredients for the pharmaceutical and fine chemical industries.
Basel/Switzerland — Micro-Macinazione registered sales of approx. $ 20,56 million in 2016, has 120 employees and is based in Monteggio, Switzerland. The acquisition was completed on 26th July 2017. Financial details of the deal were not disclosed.
With the acquisition of Micro-Macinazione Lonza becomes a leadeing company in the field of micronization services by building on Lonza/Capsugel’s existing micronization clinical and commercial manufacturing capabilities that are based in Quakertown, USA. The company strengthened its micronization offering to customers in January 2016 when it acquired Powdersize and has since invested in additional capacity at this site which came on stream in early 2017.
Lonza’s Pharma & Biotech COO, Marc Funk, commented: “Micronization is an attractive technology for Lonza given its applications across many of the high growth areas of the pharma market. Micro-Macinazione provides micronization technology and expertise that complements our existing US capabilities and provides significant additional capacity to support our growth.”
According to the manufacturer, their customers are increasingly looking for external partners to help them assess early-stage compounds and to improve product design by using micronization and sub-micronization to address key challenges of active pharmaceutical ingredients (API) development. A key focus for the new combined business will be highly potent APIs (HPAPIs) where Micro-Macinaziones’s pilot to commercial scale HPAPI offerings and the company’s recent HPAPI capacity expansion at Quakertown, provide the capacity and expertise needed to serve this growing area of the pharmaceutical market.
Micronization via jet milling is an established technique for enhancing the overall bioavailability of drug products by reducing or controlling the particle size of the API. By improving bioavailability, lower drug doses can be prescribed, potentially reducing a patient’s side effects.